Previously approved in 1998 to treat bladder cancer and discontinued in 2002 by then-manufacturer Anthra Pharmaceuticals, valrubicin (Valstar) may make another debut, this time from Valera Pharmaceuticals. Valera has just completed its acquisition of the NDA for the drug, and the company said it hopes to have the product available by the end of 2006.
The second coming of valrubicin
Previously approved in 1998 to treat bladder cancer and discontinued in 2002 by then-manufacturer Anthra Pharmaceuticals, valrubicin (Valstar) may make another debut, this time from Valera Pharmaceuticals. Valera has just completed its acquisition of the NDA for the drug, and the company said it hopes to have the product available by the end of 2006. Valrubicin is an anthracycline derivative used as an intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder. Valera said it expects to sell the treatment directly to urologists to be administered as an office procedure.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Podcast: Discussing the Shared Central Fulfillment Solution with iA
May 6th 2024Brian Nowosielski, associate editor with Drug Topics, sat down with Tom Utech and Reed Richardson of iA, an innovative pharmacy fulfillment company. Utech, CEO of iA, and Richardson, Chief Commercial Officer of iA, discussed the company's new shared central fulfillment solution. The new solution, designed to streamline processes within the pharmacy, is a technological innovation with life-saving benefits for patients.